Lilly direct-selling Zepbound at $499/mo — compare with 11 other programs →
glpzoom

Ozempic vs Mounjaro: which is better for diabetes?

Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of June 2026; updated when guidance or availability changes.
Both Ozempic and Mounjaro are FDA-approved for type 2 diabetes and both produce excellent A1c reduction. Mounjaro (tirzepatide) typically achieves slightly better A1c lowering and substantially more weight loss than Ozempic (semaglutide) in head-to-head trials (SURPASS studies). Ozempic has a longer real-world safety record (FDA-approved 2017 vs Mounjaro 2022) and additional FDA-approved indications for cardiovascular and kidney risk reduction in T2D patients. Coverage and cost are usually similar for both as diabetes medications. The right choice depends on individual factors: patients prioritizing maximum A1c reduction and weight loss may favor Mounjaro; patients with established cardiovascular disease may favor Ozempic for its proven CV outcomes data. For patients without diabetes seeking weight loss alone, the relevant comparison is Wegovy vs Zepbound (the weight-loss-indicated versions).

Where to start

Licensed US telehealth services that handle this. We may earn a commission when you sign up. See disclosure.

  • Ro logo

    Ro

    from $145/mo
    • Best for insured patients
    • Best for clinical oversight

    Ro Body — branded GLP-1 weight care program

    Visit Ro →Read review

Drugs referenced

Related questions

  • What's the difference between Zepbound and Mounjaro?

    Zepbound and Mounjaro are both tirzepatide — exactly the same active ingredient made by Eli Lilly. The difference is the FDA-approved indication: Zepbound is approved specifically for chronic weight management, while Mounjaro is approved for type 2 diabetes. Insurance coverage typically follows indication: Mounjaro is more often covered (as a diabetes drug)

  • Wegovy vs Zepbound: which is more effective?

    In separate Phase 3 trials, Zepbound (tirzepatide 15mg) produced ~20% mean body weight loss vs Wegovy (semaglutide 2.4mg) at ~15%. A head-to-head trial (SURMOUNT-5) confirmed Zepbound's edge. That said, individual response varies widely: some patients lose more on semaglutide than tirzepatide, others tolerate one's side-effect profile better than the other.

We may earn a commission when you click links to partners. Affiliate disclosure.